DFTXNMSHealthcare·Biotechnology#97 in industry

Definium Therapeutics, Inc.

Reports in 11d· 2026-05-07

+19.6% · 90d

$20.90

-1.58 (-7.01%)

News

(1)

April 2026

Apr 22, 20265 days ago8-KHealthcare

DFTX advances DT120 ODT trials, targeting NDA with three clinical readouts

DFTXDefinium Therapeutics, Inc.

# 📋 What This Document Is 🚀 This filing is an 8-K, which is a highly important filing used by companies to quickly announce major, unscheduled corporate events. This specific filing is related to an Investor and Analyst Day, meaning it serves as a deep dive into Definium Therapeutics' (DFTX) prog

Read summaryView on SEC EDGAR

Key Data

Market Cap$2.08B

Open$22.50

Prev Close$22.48

Day Range$20.88 – $22.88

52W Range$6.03 – $26.25

Volume1,406,099

P/E (TTM)—

EPS$-2.06

Dividend Yield—

Beta2.56

Price Target$38.87(+85.9%)

Next Earnings2026-05-07(11d)

Analyst Ratings

Strong Buy16 analysts

Buy 16Hold 0Sell 0

About

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Healthcare · Biotechnology

105 employees

definiumtx.com